Clinical Trial Update: Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of BMS-945429 in psoriatic arthritis patients not responding to NSAIDs or non-biologic DMARDs has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• BMS-945429

Snippet

Sponsor: CSL Behring | Conditions: Arthritis, Psoriatic | Phase 2 | Status: COMPLETED | Results posted: 2021-11-05